We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Urine Test Diagnoses River Blindness Infection

By LabMedica International staff writers
Posted on 11 Mar 2013
A telltale molecular marker for onchocerciasis or river blindness has been discovered that may lead to a potential field test. More...


The newly discovered biomarker is secreted by Onchocerca volvulus worms during an active infection and as it is detectable in patients' urine, and it could form the basis of a portable, field-ready test with significant advantages over current diagnostic methods.

Scientists at The Scripps Research Institute (La Jolla, CA, USA) analyzed onchocerciasis-positive urine samples that were collected in characterized endemic areas in Africa, and their status was confirmed by either positive skin snip (microfilaria-positive) or nodule palpation (nodule-positive). O. volvulus negative urine control samples were also obtained from healthy donors from the USA.

The investigators used liquid chromatography-mass spectroscopy based urine metabolome analysis for the identification of a diagnostic marker of O. volvulus that appears only during an active, microfilariae-producing infection and that could determine both the presence and the severity of disease. They measured the concentrations of hundreds of small-molecule metabolites in the samples and found a unique biomarker, a neurotransmitter derived secretion metabolite from O. volvulus, called N-acetyltyramine-O,β-glucuronide (NATOG).

In urine samples from Africans with active onchocerciasis infections, the scientists found that levels of the biomarker were on average four to six times higher than in samples from Africans with nonactive infections. In a separate test, the team determined that a full course of doxycycline treatment, which sterilizes or kills infecting worms by destroying their symbiotic bacteria, Wolbachia pipientis, also reduced levels of the biomarker to near-normal. The metabolome-mining approach in theory should be applicable to the development of diagnostic tests for other worm diseases.

Daniel Globisch, PhD, the senior author of the study, said, "This biomarker appears to be specific for an active infection, The wide gap between biomarker levels in active and non-active infections suggests that a field test based on the biomarker would be robustly useful." Kim D. Janda, PhD, a professor at Scripps said, " Ultimately for this to be of value in Third World countries we will need to morph this biomarker into something that's inexpensive, simple to use, tolerant of extreme temperatures and portable, basically distilling our finding to a test that can be carted around in a backpack." The study was published on February 25, 2013, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

The Scripps Research Institute



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.